Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Path to drugging functional clones of luminal breast cancers using in-depth proteomics with spatially resolved mass spectrometry guided by MALDI imaging

View ORCID ProfileN. Hajjaji, View ORCID ProfileS. Aboulouard, View ORCID ProfileT. Cardon, D. Bertin, View ORCID ProfileYM. Robin, View ORCID ProfileI. Fournier, View ORCID ProfileM. Salzet
doi: https://doi.org/10.1101/2021.02.16.21251694
N. Hajjaji
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
2Breast Cancer Unit, Oscar Lambret Center, F-59000 Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for N. Hajjaji
  • For correspondence: n-hajjaji@o-lambret.fr isabelle.fournier@univ-lille.fr michel.salzet@univ-lille.fr
S. Aboulouard
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S. Aboulouard
T. Cardon
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for T. Cardon
D. Bertin
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
2Breast Cancer Unit, Oscar Lambret Center, F-59000 Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YM. Robin
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
2Breast Cancer Unit, Oscar Lambret Center, F-59000 Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for YM. Robin
I. Fournier
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
3Institut universitaire de France, 75000 Paris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for I. Fournier
  • For correspondence: n-hajjaji@o-lambret.fr isabelle.fournier@univ-lille.fr michel.salzet@univ-lille.fr
M. Salzet
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
3Institut universitaire de France, 75000 Paris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Salzet
  • For correspondence: n-hajjaji@o-lambret.fr isabelle.fournier@univ-lille.fr michel.salzet@univ-lille.fr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Integrating tumor heterogeneity in the drug discovery process is a key challenge to tackle breast cancer resistance. Identifying protein targets for functionally distinct tumor clones is particularly important to tailor therapy to the heterogeneous tumor subpopulations. For this purpose, we performed an unsupervised, label-free, spatially resolved shotgun proteogenomic guided by MALDI mass spectrometry imaging (MSI) on 124 selected tumor clonal areas from early luminal breast cancers, tumor stroma, and breast cancer metastases. 2868 proteins were identified. The main protein classes found in the clonal proteome dataset were enzymes, cytoskeletal proteins, membrane-traffic, translational or scaffold proteins, or transporters. As a comparison, gene-specific transcriptional regulators, chromatin related proteins or transmembrane signal receptor were more abundant in the TCGA dataset. Moreover, 26 mutated proteins have been identified. Similarly, expanding the search to alternative proteins databases retrieved 126 alternative proteins in the clonal proteome dataset. The majority of these alternative proteins were coded mainly from non-coding RNA. To fully understand the molecular information brought by our approach and its relevance to drug target discovery, the clonal proteomic dataset was further compared to the TCGA breast cancer database and two transcriptomic panels, BC360 (nanoString®) and CDx (Foundation One®). We retrieved 139 pathways in the clonal proteome dataset. Only 55% of these pathways were also present in the TCGA dataset, 68% in BC360 and 50% in CDx. Seven of these pathways have been suggested as candidate for drug targeting, 22 have been associated with breast cancer in experimental or clinical reports, the remaining 19 pathways have been understudied in breast cancer. Among the anticancer drugs, 35 drugs matched uniquely with the clonal proteome dataset, with only 7 of them already approved in breast cancer. The number of target and drug interactions with non-anticancer drugs (such as agents targeting the cardiovascular system, metabolism, the musculoskeletal or the nervous systems) was higher in the clonal proteome dataset (540 interactions) compared to TCGA (83 interactions), BC360 (419 interactions), or CDx (172 interactions). Thus, we described the non-redundant knowledge brought by this approach compared to TCGA or transcriptomic panels, the targetable proteins identified in the clonal proteome dataset, and the potential of this approach for drug discovery and repurposing through drug interactions with antineoplastic agents and non-anticancer drugs.

Significance Spatially resolved mass spectrometry guided by MALDI MS imaging is a precision oncology tool to map and profile breast cancer proteomic clones with the aim of integrating tumor heterogeneity in the target discovery process to develop clone-tailored therapeutic strategies in breast cancer.

Highlights

  • Spatially resolved mass spectrometry guided by MALDI mass spectrometry imaging allows an in-depth proteomic profiling of breast cancer functional clones.

  • This unsupervised and unlabeled technology performed on intact tumors provides a multidimensional analysis of the clonal proteome including conventional proteins, mutated proteins, and alternative proteins.

  • The rich clonal proteomic information generated was not redundant with TCGA or transcriptomic panels, and showed pathways exclusively found in the proteomic analysis.

  • A large proportion of the proteins in the clonal proteome dataset were druggable with both antineoplastic agents and non-anticancer drugs, showing the potential application to drug repurposing.

  • A significant number of the proteins detected had partially or not yet known drug interactions, showing the potential for discovery.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

N/A

Funding Statement

This work was funded by Inserm and Centre Oscar Lambret.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval and consent to participate: All the analyses of this retrospective study were approved by the local Research and Ethics Committee (Centre Oscar Lambret) in accordance with the French and European legislation. Prior to the analyses, patients signed an informed consent and authorization form for the use of their data and biological samples. No personal information was used in these experiments, and a random number was assigned to each sample.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All raw data are available as supplementary material files and on ProteomeXchange with identifier PXD024134.

  • Abbreviations

    ABC
    advanced breast cancer
    ACN
    acetonitril
    AGC
    automatic gain control
    AltProt
    alternative proteins
    ANOVA
    analysis of variance
    ATC
    anatomical therapeutic chemical
    BC
    breast cancer
    Da
    dalton
    DMFS
    distant metastases free survival
    EBC
    early breast cancer
    EMA
    european medicines agency
    FDA
    food and drug administration
    FDR
    false discovery rate
    FFPE
    formalin-fixed paraffin-embedded
    HCCA
    hydroxycinnamic acid
    HER2
    human epidermal growth factor receptor-2
    HR
    hazard ratio
    HUGO
    human genome organization
    ID
    identification
    IDG
    illuminating the druggable genome
    IDG-KMC
    illuminating the druggable genome knowledge management center
    ITO
    indium tin oxide
    LC
    liquid chromatography
    LESA
    liquid extraction surface analysis
    LFQ
    label-free quantification
    MALDI
    matrix assisted laser desorption ionization
    MeOH
    methanol
    Meta
    metastases
    MS
    mass spectrometry
    MSI
    mass spectrometry imaging
    OS
    overall survival
    PMDA
    pharmaceuticals and medical devices agency
    PSM
    peptide spectrum matches
    SNP
    single nucleotide polymorphism
    TDL
    target development level
    TFA
    trifluoroacetic acid
    TIC
    total ion count
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted February 19, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Path to drugging functional clones of luminal breast cancers using in-depth proteomics with spatially resolved mass spectrometry guided by MALDI imaging
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Path to drugging functional clones of luminal breast cancers using in-depth proteomics with spatially resolved mass spectrometry guided by MALDI imaging
    N. Hajjaji, S. Aboulouard, T. Cardon, D. Bertin, YM. Robin, I. Fournier, M. Salzet
    medRxiv 2021.02.16.21251694; doi: https://doi.org/10.1101/2021.02.16.21251694
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    Path to drugging functional clones of luminal breast cancers using in-depth proteomics with spatially resolved mass spectrometry guided by MALDI imaging
    N. Hajjaji, S. Aboulouard, T. Cardon, D. Bertin, YM. Robin, I. Fournier, M. Salzet
    medRxiv 2021.02.16.21251694; doi: https://doi.org/10.1101/2021.02.16.21251694

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (76)
    • Allergy and Immunology (194)
    • Anesthesia (54)
    • Cardiovascular Medicine (488)
    • Dentistry and Oral Medicine (89)
    • Dermatology (56)
    • Emergency Medicine (168)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
    • Epidemiology (5661)
    • Forensic Medicine (3)
    • Gastroenterology (215)
    • Genetic and Genomic Medicine (856)
    • Geriatric Medicine (88)
    • Health Economics (229)
    • Health Informatics (759)
    • Health Policy (388)
    • Health Systems and Quality Improvement (250)
    • Hematology (105)
    • HIV/AIDS (181)
    • Infectious Diseases (except HIV/AIDS) (6455)
    • Intensive Care and Critical Care Medicine (388)
    • Medical Education (116)
    • Medical Ethics (28)
    • Nephrology (90)
    • Neurology (845)
    • Nursing (44)
    • Nutrition (141)
    • Obstetrics and Gynecology (161)
    • Occupational and Environmental Health (258)
    • Oncology (514)
    • Ophthalmology (162)
    • Orthopedics (44)
    • Otolaryngology (105)
    • Pain Medicine (47)
    • Palliative Medicine (21)
    • Pathology (149)
    • Pediatrics (248)
    • Pharmacology and Therapeutics (146)
    • Primary Care Research (113)
    • Psychiatry and Clinical Psychology (959)
    • Public and Global Health (2222)
    • Radiology and Imaging (375)
    • Rehabilitation Medicine and Physical Therapy (174)
    • Respiratory Medicine (311)
    • Rheumatology (109)
    • Sexual and Reproductive Health (80)
    • Sports Medicine (82)
    • Surgery (118)
    • Toxicology (25)
    • Transplantation (34)
    • Urology (42)